Intelligence · Clinical Pipeline
ALMIRALL S.P.A Pipeline
All ClinicalTrials.gov programs at ALMIRALL S.P.A — phase, modality, and trial IDs.
- Programs
- 3
Quick answer
ALMIRALL S.P.A has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
LAD328, SODIUM CHLORIDE
Almirall, S.A.
moderate-to-severe hidradenitis suppurativa
1 trial -
Placebo for LAD603, LAD603
Almirall, S.A.
Alopecia areata
1 trial -
SODIUM CHLORIDE, ADALIMUMAB, LAD191, LAD191 placebo
Almirall, S.A.
Moderate-to-severe hidradenitis suppurativa
1 trial
Frequently asked questions
How many pipeline programs does ALMIRALL S.P.A have?
3 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs